Nigerian pharma tycoon Fidelis Ayebae’s stake surges past $21 million
Fidelis Ayebae’s Fidson stake tops $21 million after a 158% stock rally, driven by growing demand for local drugs.
Fidelis Ayebae
Fidelis Ayebae's Fidson partners with Japanese firm to expand Nigeria drug production
Fidson Healthcare expands partnership with Japan’s Ohara to boost local drug production, cut reliance on imports, and improve access to affordable medicines.
Fidelis Ayebae retires as Fidson CEO after building Nigerian drugmaker into $66 million giant
Ayebae steps down as Fidson CEO after 30 years; firm posts $3.97 million profit and plans $20 million capital raise.
Fidson stake held by Nigerian tycoon Fidelis Ayebae rises by $2.4 million
Over the past 30 days, his stake has surged by N3.8 billion ($2.4 million), propelling the market value of his stake above $13 million.
Fidson stake held by Nigerian tycoon Fidelis Ayebae tops $10 million
Since the start of the year, his stake has risen by N4.94 billion ($3.08 million), thanks to a steady rally in Fidson’s share price.
Fidson, led by Fidelis Ayebae, declares $1.49 million dividend for shareholders
The payout reflects the pharmaceutical group’s focus on rewarding investors following an impressive financial performance in 2024.
Nigerian pharma tycoon Fidelis Ayebae’s Fidson posts $3.41 million profit in 2024
This growth was driven by a surge in sales of ethical and OTC products, reinforcing Fidson’s position as a top player in Nigeria’s pharmaceutical industry.
Nigerian pharma tycoon Fidelis Ayebae's Fidson receives support to expand production capacity
The collaboration with NEXIM is expected to position Fidson for a stronger presence in Africa's rapidly expanding pharmaceutical market.
Fidson, owned by Fidelis Ayebae, plans $100-million medicine production plant in Lekki FTZ
This move aligns with the company’s efforts to bolster Nigeria’s self-sufficiency in healthcare, focusing on combating the country's ongoing HIV crisis.
Fidson, owned by Nigerian tycoon Fidelis Ayebae, strikes deal to establish pharmaceutical plant
The deal is part of a broader initiative to enhance self-sufficiency in Africa’s healthcare infrastructure, particularly in the battle against HIV.
Nigerian tycoon Fidelis Ayebae’s Fidson achieves revenue exceeding $37 million in 2023
The surge in revenue is linked to the heightened sales of ethical products, including infusions, capsules, and tablets.
Nigerian tycoon Fidelis Ayebae gains $1.1 million from Fidson stake
Ayebae, a banker turned accomplished industrialist, owns a 33.1-percent stake in the pharmaceutical company, which translates to 759,643,749 ordinary shares.
Nigerian tycoon Fidelis Ayebae gains $1.4 million from investment in Fidson
The recent gains solidify Ayebae’s position as one of Africa’s pharmaceutical industry magnates.
Nigerian tycoon Fidelis Ayebae loses over $1 million from Fidson stake
Ayebae owns an impressive 33.1-percent stake in Fidson Healthcare.
Nigerian pharma tycoon Fidelis Ayebae’s stake in Fidson is now worth $14.8 million
Under Ayebae’s guidance, Fidson Healthcare has achieved exceptional financial growth, reporting a significant increase in profits for the 2022 fiscal year.